S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas.

Authors:
Mehdi A; Attias M; Arakelian A; Szyf M; Piccirillo CA and 1 more

Journal:
Neoplasia

Publication Year: 2023

DOI:
10.1016/j.neo.2022.100874

PMCID:
PMC9840362

PMID:
36638586

Journal Information

Full Title: Neoplasia

Abbreviation: Neoplasia

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

Evidence found in paper:

"Acknowledgements and Funding The study was supported by the Canadian Institutes of Health Research (CIHR) grants, PJT-156225 and PJT-148821, awarded to Shafaat A. Rabbani and Ciriaco A. Piccirillo, respectively. Ali Mehdi is recipient of Fonds de recherche du Québec – Santé (FRQ-S) scholarship."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025